First province begins funding new life-extending treatment for patients with rare lung disease
Vancouver, BC/Hamilton, ON (Tuesday, March 6, 2018) – The Pulmonary Hypertension Association of Canada (PHA Canada) and Scleroderma Canada (SC) were unanimous today in their praise of the Quebec government for swiftly providing public funding for Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH). Effective as of March 1, 2018, this action stems from the recent conclusion of pricing negotiations for Uptravi by the pan-…
Kidney Disease Patients with Pulmonary Hypertension Face Poorer Outcomes, Study Finds
Many people with chronic kidney disease also have pulmonary hypertension, a condition that increases their risk of heart problems and death, a review of 16 studies found. Doctors refer to health problems that can damage the heart muscle as cardiovascular events. They include a heart attack, an irregular heartbeat, or a blood clot in the heart or lungs.
Idiopathic PAH-Associated Hypoxemia Linked to Poor Survival, Increased Comorbidities
Hypoxemia in individuals with heritable pulmonary arterial hypertension (HPAH) or idiopathic PAH (IPAH) is associated with increased mortality risk, a greater number of comorbidities, and reduced precapillary pulmonary hypertension severity than in patients without hypoxemia, according to findings from a retrospective study published in PLoS One.
Tracleer Increased Survival of Patients with Pulmonary Hypertension Due to IPF, Trial Shows
Actelion Pharmaceuticals’ Tracleer (bosentan) increased the overall survival and reduced the hospitalizations of patients with pulmonary hypertension stemming from idiopathic pulmonary fibrosis, or IPF-PH, a Japanese clinical trial shows.
#TakeActionPAH: Making UPTRAVI available to all Canadians
This month – two years after the bad news about the Opsumit© negotiations – pCPA announced that a pricing agreement has been reached for Uptravi©. This now creates the conditions for individual provinces and territories to immediately make Uptravi© available to patients in need through their public drug plans. We aren’t there just yet – and we will still need your help to get over the finish line – but today we deserve to celebrate this important…
Study on Pulmonary Arterial Hypertension treatment tool exceeds 100 patient enrolment
A clinical-stage biotherapeutics company today announced that enrollment in its Phase 3 INOvation-1 study evaluating INOpulse® in patients with pulmonary arterial hypertension (PAH) now exceeds 100 patients, representing more than half of the anticipated enrollment.
Living Life Without Regrets: Lessons Learned from Transplant
I would tell a person considering being listed for transplant that they have to do what is right for them. I personally had a great experience with my transplant, but I have also had two friends pass away from complications after transplant. The most important thing to do is listen to your PH team, and when they think it is time for surgery, you have to really listen and decide if it is a journey you would like to embark on. The individual should…
World PH Day 2018
Saturday May 5, 2018, marks the 7th annual World PH Day, a global event dedicated to raising awareness of pulmonary hypertension (PH). World PH Day is a global awareness event, but everyone can participate on a local scale! Celebrating World PH Day helps raise awareness of PH, but it is also a way to celebrate the strength and resilience of the PH community worldwide. On May 5th, we also celebrate developments in areas of PH research and treat…
Pulmonary Hypertension in CF Patients Worsens Lung Function but Not Survival, Analysis Says
Development of pulmonary hypertension (PH) in cystic fibrosis (CF) patients compromises lung function and blood-gas parameters, but does not significantly worsen survival, an analysis suggests. The study, “Prognostic significance of pulmonary hypertension in patients with cystic fibrosis: A systematic review and meta-analysis,” was published in the journal Medicine. It was the result of joint work between researchers at the West China Hospital…
Improving Prognosis in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension
An interim report of a long-term ongoing prospective single-center study evaluating the effects of bosentan on idiopathic pulmonary fibrosis (IPF)-associated pulmonary hypertension (PH) was published in BMC Pulmonary Medicine. The results of the study to date suggest that a subset of patients with IPF may experience clinical improvements as well as better prognosis with bosentan therapy.
Recent News


Get the latest on PH treatments, community events and more when you subscribe to our newsletter